Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509542-35-00

Acronym

MK-4830-001

Enrollment

147

Registered

2024-03-18

Start date

2020-03-02

Completion date

2025-09-23

Last updated

2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Mesothelioma, Advanced/Met Gastric or GEJ adenocarcinoma, Advanced/Met HNSCC, Advanced/Met NSCLC, Advanced Pancreatic cancer, Advanced Solid tumors(coformulation), Advance/Met RCC, Ovarian Cancer. TNBC, PD-1-exposed Advanced/Met HNSCC, Unresectable Glioblastoma and Variants

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Greece, Poland, Spain

Outcome results